Techno Medica Co., Ltd. (JP:6678)
:6678
Want to see JP:6678 full AI Analyst Report?
Top Page
Techno Medica Co., Ltd.
(6678)
Select Model
Select Model
Rating:78Outperform
Price Target:
¥2,393.00
▲(6.59% Upside)
Action:Reiterated
Date:05/13/26
The score is driven primarily by strong financial strength (notably a debt-free balance sheet) and attractive valuation supported by a high dividend yield and reasonable P/E. These positives are partially offset by weaker technical signals, with the stock trading below key moving averages and a negative MACD.
Positive Factors
Debt-free balance sheet
Zero reported debt materially lowers financial risk and gives management durable optionality: funds for R&D, equipment, dividends or opportunistic M&A without refinancing pressure. This conservatism strengthens resilience through cycles and preserves long-term strategic flexibility.
Negative Factors
Uneven revenue growth
Revenue and profit swings (declines in some years, rebound in 2026) point to inconsistent demand or product cycle exposure. This undermines predictability for capacity planning and long-term investment, making durable growth planning and forecasting more challenging.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt materially lowers financial risk and gives management durable optionality: funds for R&D, equipment, dividends or opportunistic M&A without refinancing pressure. This conservatism strengthens resilience through cycles and preserves long-term strategic flexibility.
Read all positive factors
Techno Medica Co., Ltd. (6678) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥17.91B
Dividend Yield3.02%
Average Volume (3M)5.40K
Price to Earnings (P/E)15.1
Beta (1Y)0.60
Revenue Growth13.43%
EPS Growth7.06%
CountryJP
Employees237
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)122.32
Shares Outstanding8,760,000
10 Day Avg. Volume4,730
30 Day Avg. Volume5,400
Financial Highlights & Ratios
PEG Ratio2.14
Price to Book (P/B)1.12
Price to Sales (P/S)1.44
P/FCF Ratio15.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Techno Medica Co., Ltd. Business Overview & Revenue Model
Company Description
Techno Medica Co., Ltd. engages in the research and development, manufacture, sale, import, and export of in-vitro diagnostic analyzers in Japan. The company offers test tube preparation, automatic urine aliquot, RFID specimen management, and RFID...
How the Company Makes Money
null...
Techno Medica Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.66B | 11.24B | 9.91B | 10.28B | 9.37B | 9.70B |
| Gross Profit | 4.73B | 5.24B | 4.88B | 5.10B | 4.59B | 4.78B |
| EBITDA | 1.15B | 1.76B | 1.40B | 1.95B | 1.76B | 1.96B |
| Net Income | 847.54M | 1.07B | 1.00B | 1.35B | 1.15B | 1.28B |
Balance Sheet | ||||||
| Total Assets | 16.66B | 17.97B | 17.94B | 17.43B | 19.44B | 18.51B |
| Cash, Cash Equivalents and Short-Term Investments | 8.67B | 8.98B | 9.06B | 8.59B | 11.75B | 11.52B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.73B | 3.56B | 3.55B | 3.62B | 3.06B | 2.86B |
| Stockholders Equity | 13.93B | 14.41B | 14.39B | 13.82B | 16.39B | 15.65B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.07B | 952.67M | 1.10B | 748.50M | 2.00B |
| Operating Cash Flow | 0.00 | 1.10B | 977.53M | 1.14B | 887.24M | 2.06B |
| Investing Cash Flow | 0.00 | -39.76M | -32.34M | -100.72M | -155.37M | 2.49B |
| Financing Cash Flow | 0.00 | -1.15B | -470.16M | -4.21B | -505.09M | -598.64M |
Techno Medica Co., Ltd. Technical Analysis
Negative
2245.00
Price Trends
2279.83
Negative
2286.31
Negative
2099.65
Positive
Market Momentum
-54.11
Positive
43.08
Neutral
9.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6678, the sentiment is Negative. The current price of 2245 is above the 20-day moving average (MA) of 2187.15, below the 50-day MA of 2279.83, and above the 200-day MA of 2099.65, indicating a neutral trend. The MACD of -54.11 indicates Positive momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 9.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6678.
Techno Medica Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥17.91B | 15.06 | ― | 3.02% | 13.43% | 7.06% | |
67 Neutral | ¥8.94B | 16.33 | ― | 1.89% | 6.09% | -6.33% | |
61 Neutral | ¥249.58B | 16.30 | ― | 1.92% | 4.29% | 3.92% | |
55 Neutral | ¥96.14B | 27.16 | ― | 2.31% | 3.35% | 74.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥18.67B | 53.77 | ― | 3.12% | -4.77% | ― | |
47 Neutral | ¥130.02B | 279.88 | 2.42% | 3.73% | 0.78% | -95.37% |
* Healthcare Sector Average
JP:6678
Techno Medica Co., Ltd.
2,086.00
352.69
20.35%
JP:6523
PHC Holdings Corp.
1,044.00
125.25
13.63%
JP:4549
Eiken Chemical Co., Ltd.
3,005.00
1,059.80
54.48%
JP:6849
Nihon Kohden Corporation
1,494.00
-134.71
-8.27%
JP:7600
Japan Medical Dynamic Marketing, Inc.
718.00
199.68
38.52%
JP:7963
Koken Ltd.
1,867.00
238.20
14.62%
Techno Medica Co., Ltd. Corporate Events
Techno Medica Lifts Profit and Doubles Dividend on Strong FY2026 Results
May 11, 2026
Techno Medica reported a strong recovery in its non-consolidated results for the fiscal year ended March 31, 2026, with net sales rising 13.4% to ¥11.24 billion and operating profit climbing 28.3% to ¥1.67 billion. Ordinary profit increa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.